Lumito (LUMITO) Q3 2024 earnings summary

Executive summary

• Achieved CE-marking for SCIZYS scanner, enabling sales to research labs in the EU and marking transition to commercial phase.

• Focus on commercializing SCIZYS, expanding customer dialogues, and strengthening sales team with new expertise.

• Entered Letters of Intent with Katana Labs GmbH and a scientific advisor post-period, supporting commercialization.

Financial highlights

• Q3 net sales were 0 TSEK (0 TSEK last year); net loss after tax was -10,843 TSEK (-5,358 TSEK last year).

• For Jan–Sep, net sales reached 17 TSEK (0 TSEK); net loss after tax was -26,088 TSEK (-20,027 TSEK last year).

• Cash flow from operations after working capital changes was -5,567 TSEK in Q3 and -21,814 TSEK for Jan–Sep.

• Cash and cash equivalents at period end were 26,170 TSEK (22,121 TSEK last year).

• Equity at period end was 96,589 TSEK (109,950 TSEK last year); equity ratio 79% (95%).

Outlook and guidance

• Priority is to establish SCIZYS in the market and drive growth through research collaborations and "Scanning as a service".

• Strategy is to generate research segment revenues while building knowledge for future clinical product launch.

• Focus on expanding customer base, especially in pre-clinical drug development, and strengthening commercial partnerships.